Last update 18 Jun 2025

ALXN-2030

Overview

Basic Info

Drug Type
siRNA
Synonyms
ALXN 2030, ALXN2030
Target
C3
Action
inhibitors
Mechanism
C3 inhibitors(Complement C3 inhibitors)
Therapeutic Areas
Urogenital DiseasesImmune System Diseases
Active Indication
Renal transplant rejectionKidney Diseases
Inactive Indication-
Originator Organization
Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc.
Active Organization
Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc.AstraZeneca PLCAstraZeneca PLC
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our RNA technology data.
login
or
view full example data
Boost your research with our RNA technology data.

Related

2
Clinical Trials associated with ALXN-2030
NCT06744647
/ Active, not recruitingPhase 2
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN2030 in Adult Patients With Antibody-Mediated Rejection After Kidney Transplantation
NCT05501717
/ Active, not recruitingPhase 1
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Subcutaneous ALXN2030 in Healthy Participants
100 Clinical Results associated with ALXN-2030
Login to view more data
100 Translational Medicine associated with ALXN-2030
Login to view more data
100 Patents (Medical) associated with ALXN-2030
Login to view more data
100 Deals associated with ALXN-2030
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Renal transplant rejectionPhase 2
United States
Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc.
07 Mar 2025
Renal transplant rejectionPhase 2
China
Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc.
07 Mar 2025
Renal transplant rejectionPhase 2
Brazil
Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc.
07 Mar 2025
Renal transplant rejectionPhase 2
Canada
Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc.
07 Mar 2025
Renal transplant rejectionPhase 2
South Korea
Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc.
07 Mar 2025
Renal transplant rejectionPhase 2
Spain
Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc.
07 Mar 2025
Renal transplant rejectionPhase 2
Taiwan Province
Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc.
07 Mar 2025
Renal transplant rejectionPhase 2
United Kingdom
Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc.
07 Mar 2025
Kidney DiseasesPhase 1
United Kingdom
AstraZeneca PLCAstraZeneca PLC
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free